Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription


1 Am J Surg Pathol
1 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Cancer Res
7 Gynecol Oncol
1 Histopathology
1 J Clin Oncol

    Am J Surg Pathol

  1. EUSCHER ED, Marques-Piubelli ML, Ramalingam P, Wistuba I, et al
    Extrauterine Mesonephric-like Carcinoma: A Comprehensive Single Institution Study of 33 Cases.
    Am J Surg Pathol. 2023;47:635-648.
    >> Share

    BMC Cancer

  2. FANALE D, Brando C, Corsini LR, Cutaia S, et al
    Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
    BMC Cancer. 2023;23:437.
    >> Share

    Cancer Chemother Pharmacol

  3. HU C, Zhang Y, Pei T, Liu P, et al
    Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Cancer Chemother Pharmacol. 2023;91:523-529.
    >> Share

    Cancer Res

  4. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    >> Share

    Clin Cancer Res

    An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.
    Clin Cancer Res. 2023 May 16:CCR-23-0652. doi: 10.1158/1078-0432.CCR-23-0652.
    >> Share

    Gynecol Oncol

  6. FENG Z, Fu Y, Li R, Li H, et al
    Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
    Gynecol Oncol. 2023;174:142-147.
    >> Share

  7. WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
    The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Gynecol Oncol. 2023;174:121-128.
    >> Share

  8. NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
    Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
    Gynecol Oncol. 2023;173:138-150.
    >> Share

  9. BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
    Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
    Gynecol Oncol. 2023;172:106-114.
    >> Share

  10. BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
    HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Gynecol Oncol. 2023;172:98-105.
    >> Share

  11. AREND R, Dholakia J, Castro C, Matulonis U, et al
    DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Gynecol Oncol. 2023;172:82-91.
    >> Share

  12. OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
    What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
    Gynecol Oncol. 2023;172:29-35.
    >> Share


  13. MIRKOVIC J, Olkhov-Mitsel E, Amemiya Y, Al-Hussaini M, et al
    Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas.
    Histopathology. 2023;82:978-990.
    >> Share

    J Clin Oncol

  14. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016